The Effect of Puncture Sites of Portal Vein in TIPS with ePTFE-Covered Stents on Postoperative Long-Term Clinical Efficacy
Table 1
Baseline characteristics of patients included in the study.
Variables
Group A ()
Group B ()
Group C ()
χ 2/F
value
Gender (M/F)
67/21
33/15
25/10
0.924
0.630
Age (y)
52.6 ± 13.5
51.8 ± 12.5
50.2 ± 12.7
0.262
0.834
Etiology of cirrhosis
2.113
0.909
HBV
68
35
26
HCV
5
2
3
Alcoholic
8
6
5
Idiopathic
6
5
2
Main preoperative symptoms
0.615
0.735
UGI bleeding
69
40
29
Refractory ascites
19
8
6
Previous ascites
39
21
18
0.604
0.739
Previous HE
5
4
2
0.382
0.826
Hydrothorax
18
11
9
0.419
0.811
Platelet count (×109/L)
80.22 ± 41.56
82.13 ± 34.82
78.65 ± 29.31
0.468
0.642
Haemoglobin (g/L)
81.32 ± 21.53
79.22 ± 22.96
78.65 ± 19.12
0.801
0.357
Serum albumin (g/L)
31.05 ± 6.23
32.54 ± 5.88
31.22 ± 6.07
0.710
0.429
Serum bilirubin (mmol/L)
23.21 ± 19.64
26.89 ± 18.76
25.63 ± 21.23
0.265
0.782
Serum creatinine (mmol/L)
78.75 ± 35.88
76.18 ± 30.21
77.57 ± 36.54
0.391
0.631
Prothrombin time (s)
15.18 ± 2.11
15.25 ± 2.15
15.22 ± 2.18
0.354
0.733
INR
1.41 ± 0.22
1.36 ± 0.34
1.39 ± 0.36
0.563
0.465
Child-Pugh score
7.46 ± 2.11
7.64 ± 1.89
7.42 ± 1.74
0.964
0.183
Child-Pugh class (A/B/C)
32/51/5
18/27/3
15/18/2
0.487
0.975
MELD score
11.81 ± 3.45
12.14 ± 4.01
11.92 ± 3.95
0.524
0.552
Pre-PSG
25.03 ± 4.42
24.40 ± 3.97
25.55 ± 4.12
1.104
0.343
Post-PSG
10.81 ± 3.10
12.14 ± 3.36
11.45 ± 3.22
0.672
0.525
Stent diameter (6/8 mm)
6/82
3/45
3/32
0.172
0.918
Lost to follow-up
9
6
4
0.165
0.921
HBV: hepatitis B virus; HCV: hepatitis C virus; HE: hepatic encephalopathy; INR: international normalized ratio; MELD: model for end-stage liver diseases; PSG: portosystemic gradient; UGI: upper gastrointestinal. ∗χ2 test
